Shulman Dorothy I, Frane James, Lippe Barbara
Department of Pediatrics, University of South Florida Morsani College of Medicine, MDC 62, , 12901 Bruce B, Downs Blvd,,Tampa, FL, 33612, USA.
Int J Pediatr Endocrinol. 2013 Feb 2;2013(1):2. doi: 10.1186/1687-9856-2013-2.
Growth rate In children is reported to have seasonal variability. There are fewer published data regarding seasonal variability while on growth hormone (GH) therapy, and none analyzing growth rate with respect to number of daylight hours.
We analyzed 11,587 3-month intervals in 2277 prepubertal children (boys ages 3-14 years, girls ages 3-12 years) with idiopathic GH deficiency from the National Cooperative Growth Study (NCGS) database. All were naive to recombinant human GH (rhGH) therapy. Data were submitted from 31 US study centers. Seasonal variation in height velocity (HV) was assumed to be associated with the average number of daylight hours during the interval of time over which HV was computed. Number of daylight hours was determined from the date of the measurement and the latitude of the study center. Other independent variables evaluated included: height standard deviation score (SDS) at the beginning of the interval, chronologic age at the beginning of the interval, time from the start of rhGH treatment to the middle of the interval, month of the year, body mass index SDS at the beginning of the interval, rhGH dose/kg, mother's height SDS, father's height SDS, and log base 10 of the maximum stimulated GH concentration.
All variables examined, except month of the year, correlated significantly with interval HV. There was significant "seasonal" variability at all latitudes, with summer annualized HV being greater than winter HV. This difference was greatest in the first year of therapy (0.146 cm/yr/daylight hour; P < 0.0001) but persisted in subsequent years (0.121 cm/yr/daylight hr; P < 0.0001). The difference increased with distance from the equator. Growth rate over the year was not different among the latitudes reflected in this North American study.
There is "seasonal" variation in growth of children on rhGH therapy that correlates with number of daylight hours. The effect is modest and is greatest in the first year of therapy. Annual growth rate appears to be equal in children among latitudes covered by the US consistent with exposure to an equal number of daylight hours over the year. The physiologic mechanism behind this seasonal variation is not yet understood.
据报道儿童的生长速率存在季节性变化。关于生长激素(GH)治疗期间季节性变化的已发表数据较少,且没有分析生长速率与日照时长的关系。
我们分析了来自国家合作生长研究(NCGS)数据库中2277名青春期前特发性生长激素缺乏儿童(男孩3至14岁,女孩3至12岁)的11587个3个月时间段的数据。所有儿童均未接受过重组人生长激素(rhGH)治疗。数据由美国31个研究中心提交。身高增长速度(HV)的季节性变化被认为与计算HV的时间段内的平均日照时长有关。日照时长根据测量日期和研究中心的纬度确定。评估的其他自变量包括:时间段开始时的身高标准差评分(SDS)、时间段开始时的实际年龄、从rhGH治疗开始到时间段中间的时间、一年中的月份、时间段开始时的体重指数SDS、rhGH剂量/千克、母亲的身高SDS、父亲的身高SDS以及最大刺激生长激素浓度的以10为底的对数。
除一年中的月份外,所有检查的变量均与时间段HV显著相关。在所有纬度地区均存在显著的“季节性”变化,夏季的年化HV大于冬季的HV。这种差异在治疗的第一年最大(0.146厘米/年/日照小时;P < 0.0001),但在随后几年中持续存在(0.121厘米/年/日照小时;P < 0.0001)。差异随着与赤道距离的增加而增大。在美国这项研究中所反映的不同纬度地区,儿童全年的生长速率没有差异。
接受rhGH治疗的儿童生长存在与日照时长相关的“季节性”变化。这种影响较小,且在治疗的第一年最大。在美国所涵盖的纬度地区,儿童的年生长速率似乎相等,这与一年中日照时长相等的情况相符。这种季节性变化背后的生理机制尚不清楚。